The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis

被引：0
作者：
Wei Wu
Huo-mu Tong
Yun-sheng Li
Jia Cui
机构：
[1] Chun’an First People’s Hospital (Zhejiang Provincial People’s Hospital Chun’an Branch),Department of Geriatrics
[2] Chun’an First People’s Hospital (Zhejiang Provincial People’s Hospital Chun’an Branch),Department of Endocrinology
来源：
Endocrine | 2024年 / 83卷
关键词：
Semaglutide; Blood pressure; Type-2 diabetes; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：571 / 584
页数：13
相关论文
共 247 条
  • [1] Cosentino F(2020)2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Eur. Heart J. 41 255-323
  • [2] Grant PJ(2021)Safety of semaglutide Front. Endocrinol. 12 645563-791
  • [3] Aboyans V(2019)Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes Clin. Pharmacokinet. 58 781-515
  • [4] Bailey CJ(2021)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 372 n71-1844
  • [5] Ceriello A(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 b2535-984
  • [6] Delgado V(2011)The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ 343 d5928-851
  • [7] Smits MM(2021)Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes N. Engl. J. Med. 385 503-1480
  • [8] Van Raalte DH(2016)Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 375 1834-286
  • [9] Granhall C(2021)Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Lancet 397 971-109
  • [10] Donsmark M(2019)Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 381 841-50
12345678910